Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers,
but the immunological mechanism and molecular determinants of primary and acquired …

Genome instability and aberrant alterations of transcriptional programs both play important
roles in cancer. Single-cell RNA sequencing (scRNA-seq) has the potential to investigate …

Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and
extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM …

Single-cell RNA sequencing is the reference technology to characterize the composition of
the tumor microenvironment and to study tumor heterogeneity at high resolution. Here we …

Over the past thirty years, the importance of chemokines and their seven-transmembrane G
protein-coupled receptors (GPCRs) has been increasingly recognized. Chemokine …

Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …

Introduction Multiple myeloma (MM) is still an incurable plasma cell malignancy. The efficacy
of immunotherapy on MM remains unsatisfactory, and the underlying molecular mechanisms …